Trials / Completed
CompletedNCT04124003
A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin
An Open-label, Single-sequence, Drug-drug Interaction Study to Assess the Effect of BMS-963272 Coadministration on the Systemic Exposure of Rosuvastatin in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rosuvastatin | Specified dose on specified days |
| DRUG | BMS-963272 | Specified dose on specified days |
Timeline
- Start date
- 2019-10-08
- Primary completion
- 2020-01-03
- Completion
- 2020-01-03
- First posted
- 2019-10-11
- Last updated
- 2020-03-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04124003. Inclusion in this directory is not an endorsement.